Health Policy

Seuraa
SPD politicians criticizing Health Minister Nina Warken's unbalanced health savings package in Bundestag debate, demanding pharma cuts.
AI:n luoma kuva

SPD criticizes imbalance in Warken's health savings package

Raportoinut AI AI:n luoma kuva

Days before the planned cabinet decision, the SPD warns against overburdening insured individuals with Health Minister Nina Warken's savings package. The SPD demands more cuts from pharmaceutical companies and efficiency measures. The Greens have presented their own counter-concept.

The Korean government's plan to extend National Health Insurance coverage to hair-loss medication is facing growing criticism from patient groups and medical experts.

Raportoinut AI

Federal Health Minister Nina Warken has called on the states to lower building standards for care homes. The goal is to reduce nursing care costs.

In an RND interview, Federal Medical Association President Klaus Reinhardt discusses Germany's high doctor visit rates, which he does not attribute solely to patient behavior. He warns against planned prescribing rights for pharmacists and advocates for a sugar tax as well as smartphone bans in schools. Additionally, he supports a new regulation of assisted suicide with strict protective measures.

Raportoinut AI Faktatarkistettu

Actress Cheryl Hines said in a recent interview with Dr. Phil McGraw that her husband, Health and Human Services Secretary Robert F. Kennedy Jr., at one point suggested the couple publicly claim they were separated to reduce the political backlash she was facing. Hines said she did not consider doing so.

In the second Trump administration, Heritage Foundation scholars are pressing Health and Human Services Secretary Robert F. Kennedy Jr. to order "gold standard" studies and expand informed-consent requirements for oral contraceptives, arguing the pills carry underappreciated health and ecological costs.

Raportoinut AI

A U.S. federal judge has ruled that the Food and Drug Administration (FDA) possesses the authority to regulate lab-developed tests (LDTs) as medical devices. This decision comes amid ongoing debates over the oversight of in-house diagnostic tools used by clinical laboratories.

 

 

 

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää